222 related articles for article (PubMed ID: 12771933)
1. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
Denoyelle C; Hong L; Vannier JP; Soria J; Soria C
Br J Cancer; 2003 May; 88(10):1631-40. PubMed ID: 12771933
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Hiraga T; Williams PJ; Ueda A; Tamura D; Yoneda T
Clin Cancer Res; 2004 Jul; 10(13):4559-67. PubMed ID: 15240548
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic Acid Inhibits the Motility of Cancer Stem-like Cells from the Human Breast Cancer Cell Line MDA-MB 231.
Bühler H; Hoberg C; Fakhrian K; Adamietz IA
In Vivo; 2016 11-12; 30(6):761-768. PubMed ID: 27815459
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions.
Okamoto S; Jiang Y; Kawamura K; Shingyoji M; Tada Y; Sekine I; Takiguchi Y; Tatsumi K; Kobayashi H; Shimada H; Hiroshima K; Tagawa M
Cell Death Dis; 2014 Nov; 5(11):e1517. PubMed ID: 25393473
[TBL] [Abstract][Full Text] [Related]
6. The combined use of Camellia sinensis and metronomic zoledronic acid in a breast cancer-induced osteolysis mouse model.
Luo KW; Ko CH; Yue GG; Gao S; Lee JK; Li G; Fung KP; Leung PC; Evdokiou A; Lau CB
J Cancer Res Clin Oncol; 2015 Jun; 141(6):1025-36. PubMed ID: 25431338
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.
Chaplet M; Detry C; Deroanne C; Fisher LW; Castronovo V; Bellahcéne A
Biochem J; 2004 Dec; 384(Pt 3):591-8. PubMed ID: 15324309
[TBL] [Abstract][Full Text] [Related]
9. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
Espinoza I; Liu H; Busby R; Lupu R
Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
[TBL] [Abstract][Full Text] [Related]
10. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro.
Mitrofan LM; Pelkonen J; Mönkkönen J
Bone; 2009 Dec; 45(6):1153-60. PubMed ID: 19699819
[TBL] [Abstract][Full Text] [Related]
11. Effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway.
Honda Y; Takahashi S; Zhang Y; Ono A; Murakami E; Shi N; Kawaoka T; Miki D; Tsuge M; Hiraga N; Abe H; Ochi H; Imamura M; Aikata H; Chayama K
J Gastroenterol Hepatol; 2015 Mar; 30(3):619-27. PubMed ID: 25167891
[TBL] [Abstract][Full Text] [Related]
12. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
Fanale D; Amodeo V; Bazan V; Insalaco L; Incorvaia L; Barraco N; Castiglia M; Rizzo S; Santini D; Giordano A; Castorina S; Russo A
Oncotarget; 2016 May; 7(20):29321-32. PubMed ID: 27081088
[TBL] [Abstract][Full Text] [Related]
13. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis.
Ohshiba T; Miyaura C; Ito A
Biochem Biophys Res Commun; 2003 Jan; 300(4):957-64. PubMed ID: 12559967
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid reduces bone loss and tumor growth in an orthotopic xenograft model of osteolytic oral squamous cell carcinoma.
Martin CK; Werbeck JL; Thudi NK; Lanigan LG; Wolfe TD; Toribio RE; Rosol TJ
Cancer Res; 2010 Nov; 70(21):8607-16. PubMed ID: 20959474
[TBL] [Abstract][Full Text] [Related]
15. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
16. Zoledronate attenuates angiogenic effects of angiotensin II-stimulated endothelial progenitor cells via RhoA and MAPK signaling.
Yang JX; Chen B; Pan YY; Han J; Chen F; Hu SJ
PLoS One; 2012; 7(10):e46511. PubMed ID: 23071580
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
[TBL] [Abstract][Full Text] [Related]
18. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.
Insalaco L; Di Gaudio F; Terrasi M; Amodeo V; Caruso S; Corsini LR; Fanale D; Margarese N; Santini D; Bazan V; Russo A
J Cell Mol Med; 2012 Sep; 16(9):2186-95. PubMed ID: 22260151
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker JM; Haider MT; DeCristo MJ; Allocca G; Brown NJ; Silver DP; Holen I; McAllister SS
Breast Cancer Res; 2017 Mar; 19(1):23. PubMed ID: 28264701
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid - a multiplicity of anti-cancer action.
Yuasa T; Kimura S; Ashihara E; Habuchi T; Maekawa T
Curr Med Chem; 2007; 14(20):2126-35. PubMed ID: 17691952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
